(Q35823836)

10 August 2017

1 reference

title

The genetic cohorts: facing the new challenges in infectious diseases. The HIV model (English)

1 reference

10 August 2017

Amalio Telenti

1

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Infectious Diseases and Clinical Microbiology

10 August 2017

published in

1 reference

10 August 2017

volume

22

1 reference

10 August 2017

issue

6

1 reference

10 August 2017

page(s)

337-341

1 reference

Individualising HIV treatment--pharmacogenetics and immunogenetics

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

HLA and HIV: modeling adaptation to moving targets

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Genetic associations: false or true?

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Pharmacogenomics and "individualized drug therapy": high expectations and disappointing achievements

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Science, medicine, and the future: susceptibility to infection

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

The era of genomics: impact on sepsis clinical trial design

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

Genetics of susceptibility to human infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2804%2973106-7

7 January 2021

10.1016/S0213-005X(04)73106-7

Identifiers

DOI

1 reference

10 August 2017

1 reference